TNG 908
Alternative Names: TNG-908Latest Information Update: 13 Nov 2024
Price :
$50 *
At a glance
- Originator Tango Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 06 Nov 2024 Pharmacodynamics data from a preclinical studies in Solid tumours released by Tango Therapeutics
- 06 Nov 2024 Updated efficacy and safety data from a phase I/II trial in Solid tumours released by Tango Therapeutics
- 06 Nov 2024 Updated efficacy data from a phase I/II trial in Solid tumours released by Tango Therapeutics